Yüklüyor......
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis
Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus (HCV) infection and was highly efficacious in phase 2 and 3 studies. Treating HCV genotype (GT) 3 infection remains a priority, as these patients are harder to cure and at a greater risk for liver steatosis, fibr...
Kaydedildi:
| Yayımlandı: | J Viral Hepat |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7379735/ https://ncbi.nlm.nih.gov/pubmed/30421537 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvh.13038 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|